A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival
in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic
disease compared with chemotherapy alone.